NCT03784677: SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: TRPV6
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors with TRPV6 overexpression
Exclusions: Patients with symptomatic uncontrolled metastasis to the central nervous system or leptomeningeal or lymphangitic carcinomatosis

Up ↑